The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Insulet's revenues will expand 60.6% and EPS will remain in the red.
The average estimate for revenue is $51.7 million. On the bottom line, the average EPS estimate is -$0.25.
Last quarter, Insulet logged revenue of $47.8 million. GAAP reported sales were 69% higher than the prior-year quarter's $28.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.31. GAAP EPS were -$0.31 for Q1 compared to -$0.22 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 42.5%, 540 basis points worse than the prior-year quarter. Operating margin was -22.8%, 290 basis points better than the prior-year quarter. Net margin was -31.0%, 390 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $215.6 million. The average EPS estimate is -$0.91.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 69 members out of 112 rating the stock outperform, and 43 members rating it underperform. Among 37 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give Insulet a green thumbs-up, and 13 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Insulet is outperform, with an average price target of $23.65.
- Add Insulet to My Watchlist.